Core Insights - Intellia Therapeutics has been a leader in the CRISPR medicine space since its inception in 2014, focusing on in vivo treatment of genetic diseases [1] - The company is on the verge of completing trials that will lead to the approval of some of the first in vivo CRISPR therapeutics [1] Clinical Trials - Intellia is currently conducting 3 Phase III trials [2] - The company has enrolled over 600 total patients, contributing to a substantial safety database [2] - Patients have been followed for over 4 years, providing extensive data on long-term safety [2] - The company has published 5 landmark publications related to its research [2]